Palawan is not included among the places in the country where the Department of Health undertook a dengue vaccination program using Dengvaxia which has been stopped by the government following findings on its adverse effects.
Dr. Peter Curameng, Provincial Department of Health Officer said that Palawan was not included in the vaccination program because the province did not have a high number of dengue incidence and was not a priority for that program.
Sanofi Pasteur, the manufacturer of the dengue vaccine recently admitted the vaccine poses risks to people who had not been infected with dengue before.
Curameng said the vaccine was distributed to the selected areas in the country including National Capital Region (NCR), Region III and IV for pilot testing.
He said that dengue cases in Palawan are minimal which is not enough basis to be given a particular anti-dengue vaccine.
“Mababa ang cases (dengue) dito sa Palawan kaya wala, doon lang ‘yan sa mga matataas ang kaso,” he said.
Curameng said that World Health Organization (WHO) does not recommend Dengvaxia vaccine in the Philippine vaccination program due to its negative effect.
“Parang ‘yong nabanggit hindi naman ‘yan ini-endorse ng WHO. ‘Yon naman ang kagandahan kasi atleast hindi tayo nasama kasi mabusisi ‘yan. Mabuti nga hindi tayo isinama,” Curameng said.
According to the national reports, WHO clarified on Tuesday that they are not made any recommendation to the Philippines and other countries to use the first dengue vaccine in the world for the national immunization programs.
The national government has also suspended to use the Dengvaxia which was already given to almost 730,000 children. The Food and Drug Administration (FDA) has suspended the sale and distribution of the anti-dengue vaccine.
Curameng said that hypertension and pneumonia are more common in Palawan than dengue.
This material may not be published, broadcast, rewritten, or redistributed. © Copyright 2018 - Qubes Publication and Ads Promotion. All rights reserved.